Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer.

Y. Okada, H. Anai, T. Hattori, Y. Maehara, J. Nishimura, K. Sugimachi, H. Nawata

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Seventeen consecutively treated patients with advanced gastric cancer were prescribed every 3 weeks intravenous cisplatin (20 mg/m2/day) and a continuous infusion of 5-fluorouracil (5-FU) (750 mg/m2/day) for 5 days. Twelve (71%) patients had been treated previously with other anticancer drugs. Seven (42%) patients showed a partial response and these responses persisted for over 4.4 months. Stabilization of the disease occurred in eight (47%) patients, and in two (12%) the disease progressed. At the time of analysis, mean survival of the responders was 8.2 months, while that of non-responders was 5.0 months. The toxicities were within acceptable limits and only a few had a grade III toxicity. This combined administration of cisplatin and 5-FU for 5 days is safe and effective for patients with advanced gastric cancer.

Original languageEnglish
Pages (from-to)453-456
Number of pages4
JournalAnti-cancer drugs
Volume2
Issue number5
DOIs
Publication statusPublished - Oct 1991

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Fingerprint Dive into the research topics of 'Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer.'. Together they form a unique fingerprint.

  • Cite this